Summary of the Conference Call for Aide Biological Company Overview - **Company**: Aide Biological - **Industry**: In Vitro Diagnostics (IVD) Key Points and Arguments Financial Performance - In the first three quarters of 2025, the company reported a revenue of **866 million yuan**, a year-on-year increase of **2.08%** [2][3] - Net profit increased by **15.5%** year-on-year, with a non-recurring net profit growth of **18.05%** [3] - A **18 million yuan** impairment provision was made for the long-term receivables related to the transfer of rights for the colorectal cancer early screening product SDC two [2][3] Share Buyback Plan - The board plans to repurchase **100 to 200 million yuan** worth of company shares, pending approval from the shareholders' meeting [2][3][17] Product Development and Approvals - NGS ten-gene lung cancer MRD research data will be disclosed at the ISMO Asia conference in December, with product registration already initiated [2][3] - New products expected to be approved in Q4 2025 include the PCR 11 gene companion diagnostic label [3][14] Market Performance - Domestic sales team adjustments are nearly complete, with good market performance expected in the first half of 2025 [2][5] - Domestic revenue grew by approximately **5%** in Q3 2025, while clinical service revenue from pharmaceutical companies declined by **14.4%** [4][11] - International sales are expected to achieve positive growth for the year, with a focus on NGS applications in collaboration with Sailu Medical [2][5] Expense Management - Sales expenses increased in Q3 2025 due to marketing and personnel costs, but the sales expense ratio is on a downward trend [6] - R&D expense ratio remains stable at **15% to 18%**, while management expenses are stable at **7% to 8%** [6] Strategic Adjustments - The company is adjusting its overseas market strategy, focusing on growth in Southeast Asia and East Asia while restructuring the sales system in the EU [7][18] - In Southeast Asia, the focus is on PCR products, while in the EU, the emphasis is on NGS products [7] Regulatory Environment - The Jiangsu Province tumor gene testing centralized procurement project has been suspended due to funding issues [4][8] - The overall environment for the domestic IVD industry in 2026 is expected to remain challenging [9] Future Outlook - The MRD product's commercialization timeline is uncertain, pending registration and approval [10] - The company remains optimistic about the future growth of its BD business despite a slowdown in revenue confirmation compared to 2024 [13] New Product Launches - Recent approvals include thyroid cancer panels and HRD products, with expectations for more approvals in Q4 2025 and Q1 2026 [14] Collaboration and Partnerships - The strategic partnership with Sailu Medical has deepened, enhancing NGS product competitiveness in overseas markets [15] - No changes in the OEM collaboration with BGI, which remains significant for overseas market penetration [15] Challenges and Industry Dynamics - The IVD industry faces challenges such as increased VAT and price pressure, but the company has achieved revenue and profit growth [24] - Future growth is anticipated from new product launches, including immunohistochemistry and Fisher technology platforms [25]